While no P(BCMA)B*18-specific T cells could be induced in MM-derived samples using our standard priming protocol, we observed de novo induction of P(BCMA)B*18-specific T cells with frequencies of 0.2–4.1% (mean 1.6%) within the CD8+ T-cell population of an MM patient upon addition of CTLA-4 and PD-1 blocking antibodies (Fig. 4a). This evidence concerns the gene CD8A and Miyoshi myopathy.